Keiko Nakamura

Keiko Nakamura

Auto-generated profile, based on publicly available information

Keiko Nakamura

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
MYMasahito Yamada
Masahito Yamada
JKJunji Komatsu
Junji Komatsu
KNKeiko Nakamura
Keiko Nakamura
KSKenji Sakai
Kenji Sakai
MSMiharu Samuraki-Yokohama
Miharu Samuraki-Yokohama
MYMitsuhiro Yoshita
Mitsuhiro Yoshita
The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

21 May 2015 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
KNKeiko Nakamura
Keiko Nakamura
FMFumiaki Mori
Fumiaki Mori
TKTomoya Kon
Tomoya Kon
KTKunikazu Tanji
Kunikazu Tanji
YMYasuo Miki
Yasuo Miki
KWKoichi Wakabayashi
Koichi Wakabayashi
The histological hallmark of multiple system atrophy (MSA) is the presence of filamentous aggregations of phosphorylated α-synuclein in oligodendrocytes, referred to as glial cytoplasmic inclusions (GCIs). Although GCIs can occur widely in the central nervous system, accumulation of phosphorylated α-synuclein in Schwann cells has not been reported in MSA. We immunohistochemically examined the cranial and spinal nerves, peripheral ganglia and visceral autonomic nervous system of patients with MSA (n = 14) and control subjects (n = 20). In MSA, accumulation of phosphorylated α-synuclein was found in the cytoplasm of Schwann cells. These Schwann cell cytoplasmic inclusions (SCCIs) were also immunopositive for ubiquitin and p62. SCCIs were found in 12 of 14 patients with MSA (85.7 %). They were most frequent in the anterior nerve of the sacral cord and, to a lesser extent, in the cranial nerves (oculomotor, glossopharyngeal-vagus and hypoglossal nerves), and spinal and sympathetic ganglia. SCCIs were rarely found in the visceral organs. Immunoelectron microscopy demonstrated that the SCCIs consisted of abnormal filaments, 15–20 nm in diameter. No such inclusions were found in controls. The present findings indicate that Schwann cells are also involved in the disease process of MSA.

1 October 2014 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
RTRyoichi Takahashi
Ryoichi Takahashi
Kenjiro OnoKenjiro Ono
Kenjiro Ono
SSShutaro Shibata
Shutaro Shibata
KNKeiko Nakamura
Keiko Nakamura
JKJunji Komatsu
Junji Komatsu
MYMasahito Yamada
Masahito Yamada

9 August 2020 in Neuropathology
Verified
Journal Article
Closed access
PDF file
KNKeiko Nakamura‐Shindo
Keiko Nakamura‐Shindo
KSKenji Sakai
Kenji Sakai
ASAi Shimizu
Ai Shimizu
CIChiho Ishida
Chiho Ishida
MYMasahito Yamada
Masahito Yamada

1 June 2020 in eNeurologicalSci
Verified
Journal Article
Open access
KNKeiko Nakamura-Shindo
Keiko Nakamura-Shindo
KOKenjiro Ono
Kenjiro Ono
KKKishin Koh
Kishin Koh
HIHiroyuki Ishiura
Hiroyuki Ishiura
STShoji Tsuji
Shoji Tsuji
MYMasahito Yamada
Masahito Yamada
Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder characterized by pyramidal weakness and spasticity of the lower limbs. SPG46, one of autosomal recessive HSP, is clinically characterized by spasticity and pyramidal weakness of the lower limbs, mental retardation, congenital bilateral cataract, thin corpus callosum, and hypogonadism in males. Mutations in the nonlysosomal glucosylceramidase β2 (GBA2) gene have been identified in patients with SPG46. A Japanese woman was identified with bilateral cataracts when she was in an elementary school. She felt falling easily, speaking unclearness, and difficulty in walking and raising her left leg in her 30s. Her neurological examination at the age of 44 revealed dysarthria, spasticity in the upper and lower extremities, increased jaw jerk and tendon reflexes in the extremities, bilateral extensor plantar reflexes, ataxia, and pollakiuria. Magnetic resonance imaging showed thinning of the corpus callosum body as well as atrophy in the pons and cerebellum. A novel homozygous c.1838A > G (p.D613G) missense mutation was detected at exon 12 in GBA2. We diagnosed her illness as an autosomal-recessive form of hereditary SPG46. The clinical features matched previously reported phenotype of SPG46. This is the first report of a Japanese patient with SPG46 with a novel mutation in GBA2. We presume that the novel GBA2 missense mutation found in our patient would cause loss of GBA2 activity, resulting in the neurological manifestations of SPG46.

4 May 2018 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
KNKeiko Nakamura
Keiko Nakamura
HKHiroyasu Kaya
Hiroyasu Kaya
TKTsutomu Kobayashi
Tsutomu Kobayashi
NSNaoaki Saito
Naoaki Saito
MYMasahito Yamada
Masahito Yamada